Arkolith/Insider Trading/CRBP/Form 4

Cohen Yuval

Chief Executive Officer, DirectorCorbus Pharmaceuticals Holdings, Inc. (CRBP) · full profile →Form 4 · filed Oct 27, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$471K
Net Open-Market Flow
-$471K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 27, 2025Sell(S)9K$17.14$154K138K
Oct 27, 2025Option exercise(M)9K$4.26$38K147K
Oct 24, 2025Sell(S)19K$17.01$317K138K
Oct 24, 2025Option exercise(M)19K$4.26$79K157K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 27, 2025Option exercise(M)9K—$022K
Oct 24, 2025Option exercise(M)19K—$031K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-251639) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML